The drug trastuzumab deruxtecan improves progression-free survival in HER2-positive breast cancer in 75.8% of patients. The results of the study, led by the International Breast Cancer Center and published in The New England Journal of Medicine, are “the most positive in history,” according to the authors.
–
:strip_icc():format(jpeg)/kly-media-production/medias/2841654/original/096329800_1561972203-tbc.jpg "Recognize Early, Here Are 5 Signs of Tuberculosis Lung Disease")
